Iressa is comparable to docetaxel in survival rate

Published: 2007-09-10 06:57:00

Updated: 2007-09-10 06:57:00

AstraZeneca Korea said on September 5 that patients with non-small cell lung cancer (NSCLC) treated with the oral anti-cancer drug Iressa (gefitinib) in the INTEREST study had equivalent (non-inferior) survival to those treated with intravenous docetaxel, citing data presented at the World Confer...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK